Genmab — Marts 2019
-
Ser ud til Revlimid får held med at beskytte patentet til 2023. https://m.firstwordpharma.com/celgene-survives-alvogens-attempt-inter-partes-review-revlimid-patent-us
-
God morgen
-
Jeg sad faktisk lige og tænkte det samme.
-
Ser ud til at anonyme har bestemt at kursen i dag skal ligge i 1131...
-
eller lavere..
-
De vil vel bare have den ned i dag...op på mandag...osv. Det er deres måde at lave penge på.
-
Der bliver længere og længere til 1280..:-(
-
Karyopharm stiger 22% på forlængelse af FDA-review https://seekingalpha.com/pr/17445029-karyopharm-announces-fda-extension-review-period-selinexor-new-drug-application
-
Ja, det er en underlig kursudvikling i Genmab - fortsat. Ville være fint med at afgørende brud væk far kurs 1200 i opadgående retning.
-
Tror jeg også.
Hvorfor skulle den falde ?Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind